{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-222189","form_type":"8-K","ticker":"TECX","cik":"0001681087","company_name":"Tectonic Therapeutic, Inc.","filed_at":"2024-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.090038+00:00","generated_at":"2026-05-31T03:38:44.291543+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tectonic reports positive Phase 1a data for TX45; Phase 2 doses selected, Phase 1b dose escalated","bullets":["Phase 1a: TX45 well-tolerated, no immunogenicity, robust PK/PD; Phase 2 doses set at 300 mg SC monthly or every other week.","Phase 1b hemodynamic trial in PH-HFpEF escalated to 3 mg/kg IV; topline results expected Q2 2025.","Phase 2 APEX trial screening initiated; topline results anticipated in 2026.","Full Phase 1a results to be presented at AHA Scientific Sessions November 2024.","Over 600,000 patients estimated with Group 2 PH-HFpEF; no approved treatments currently."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-222189","json":"https://secwatch.observer/filing/0001193125-24-222189.json","markdown":"https://secwatch.observer/filing/0001193125-24-222189.md","text":"https://secwatch.observer/filing/0001193125-24-222189.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524222189/0001193125-24-222189-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681087/000119312524222189/d667336d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:38:44.291543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}